Bausch & Lomb's gross profit for the
three
months ended in Mar. 2024 was $675 Mil. Bausch & Lomb's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $2,620 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Bausch & Lomb's gross profit for the
three
months ended in Mar. 2024 was $675 Mil. Bausch & Lomb's Revenue for the
three
months ended in Mar. 2024 was $1,099 Mil. Therefore, Bausch & Lomb's Gross Margin % for the quarter that ended in Mar. 2024 was 61.42%.
Bausch & Lomb had a gross margin of 61.42% for the quarter that ended in Mar. 2024 => Durable competitive advantage
During the past 6 years, the highestGross Margin % of Bausch & Lomb was 64.88%. The lowest was 59.69%. And the median was 61.69%.
Warning Sign:
Bausch & Lomb Corp gross margin has been in long-term decline. The average rate of decline per year is -1.6%.
Bausch & Lomb Gross Profit Historical Data
The historical data trend for Bausch & Lomb's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bausch & Lomb's Gross Profit
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb's Gross Profit Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Gross Profit distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Gross Profit falls into.
Bausch & Lomb Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Bausch & Lomb's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,620 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bausch & Lomb had a gross margin of 61.42% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Bausch & Lomb Gross Profit Related Terms
Thank you for viewing the detailed overview of Bausch & Lomb's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Bausch & Lomb (Bausch & Lomb) Business Description
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLCO has been successfully added to your 